Albert Lee
Neurology · Lafayette, INNPI 1790815322
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $464 and has fallen 67.9% since, to $149 in 2023. That places this record below the midpoint for neurology clinicians in IN, where the typical reported total is $1,614.
Across 90 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$227
- Novartis$199
- UCB, Inc.$188
- SK Life Science, Inc.$107
- Johnson & Johnson$88
- Eisai Inc.$85
- plus $648 from 17 others
What the payments were for
- Food & beverage$1,540100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $227 |
| Novartis | 13 | $199 |
| UCB, Inc. | 15 | $188 |
| SK Life Science, Inc. | 4 | $107 |
| Johnson & Johnson | 4 | $88 |
| Eisai Inc. | 3 | $85 |
| Amgen(2 entities) | 4 | $78 |
| Sanofi | 4 | $71 |
| EMD Serono, Inc. | 4 | $65 |
| Greenwich Biosciences, Inc. | 3 | $64 |
| Biohaven Pharmaceuticals, Inc. | 2 | $48 |
| GE HealthCare | 2 | $41 |
| AstraZeneca | 2 | $39 |
| Biogen | 3 | $39 |
| Neurelis, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Livanova USA, Inc. | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Banner Life Sciences, LLC | 1 | $13 |
How this compares
$1,540 in reported general payments places this provider in the 45th percentile of 308 neurology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 20 | $618 |
| Gabapentin | 17 | $240 |
Paid to pharmacies, not to this prescriber.
Other neurology in Lafayette
- Anthony SimchakLafayette$720K
- Khaled HammoudLafayette$30K
- William ConteMerrillville$1.2M
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
- Marlene BultemeyerFort Wayne$277K
- Jerry SmarttCarmel$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.